A topical cream called VTAMA, known generically as tapinarof, is changing expectations for how people with plaque psoriasis manage their condition. Approved by the FDA in May 2022, VTAMA is the first new topical chemical entity for psoriasis to reach the U.S. market in 25 years. What makes it genuinely unusual is its remittive effect: in clinical trials, patients who achieved completely clear skin maintained that clarity for a mean of about 130 days — roughly four months — after stopping treatment.
That means some patients who respond well could theoretically use the cream for as few as four to eight weeks per year, a dramatic departure from the daily, indefinite application most topical psoriasis treatments demand. For the millions of adults living with plaque psoriasis, many of whom also navigate other chronic health conditions including cognitive decline and the stresses of caregiving, the prospect of a treatment that doesn’t require constant daily attention is significant. Managing a skin condition on top of dementia care routines or brain health regimens adds real burden, and anything that simplifies the medication calendar matters. This article examines how VTAMA works, what the clinical evidence actually shows, the important caveats behind the “four weeks a year” claim, cost realities, and how this drug compares to other newer topical options.
Table of Contents
- How Does a Topical Psoriasis Drug Work for Just Four Weeks a Year?
- What the Clinical Trials Actually Found — And Where the Numbers Have Limits
- Why the Non-Steroidal Distinction Matters for Older Adults
- VTAMA vs. Roflumilast Cream — Choosing Between the New Topicals
- The Cost Problem That Shadows the Clinical Promise
- Broader Implications — Tapinarof Beyond Psoriasis
- What This Means for Psoriasis Management Going Forward
- Conclusion
- Frequently Asked Questions
How Does a Topical Psoriasis Drug Work for Just Four Weeks a Year?
The “four weeks a year” framing deserves honest unpacking, because it represents a best-case scenario rather than a universal experience. VTAMA works by activating the aryl hydrocarbon receptor, or AhR, a pathway in skin cells that helps regulate inflammation and skin barrier function. It is the first drug in this class — a true first-in-class non-steroidal topical therapy that operates through a completely different mechanism than corticosteroids, PDE4 inhibitors, or vitamin D analogs. When applied once daily to affected areas, tapinarof can induce disease remission in a meaningful percentage of patients after an initial treatment course of roughly 12 weeks. Here is where the math behind “four weeks a year” comes in. After that initial 12-week course, patients who reach complete clearance can stop applying the cream.
Because the remittive effect keeps skin clear for an average of about four months off therapy, patients can then resume treatment only when a flare returns, use the cream for a shorter cycle, achieve clearance again, and stop. Over the course of a year, these intermittent cycles could add up to just four to eight weeks of active use for strong responders. However, this is not what every patient will experience. The initial treatment alone is 12 weeks, and individual flare patterns vary widely. For someone just starting VTAMA, the first year will involve more than four weeks of use. The abbreviated timeline applies more realistically to subsequent years in patients with robust responses.
What the Clinical Trials Actually Found — And Where the Numbers Have Limits
The evidence behind VTAMA comes from three major trials known collectively as PSOARING. In the two Phase 3 randomized, double-blind trials — PSOARING 1 and PSOARING 2 — involving 1,025 subjects, 36 percent and 40 percent of patients respectively achieved clear or almost clear skin, compared to just 6 percent in the vehicle (placebo cream) groups. These are solid response rates for a topical therapy, though they also mean that the majority of patients did not reach complete or near-complete clearance. The long-term extension study, PSOARING 3, enrolled 763 patients for 52 weeks of open-label treatment. During that period, 40.9 percent achieved complete disease clearance at some point. Importantly, the study found no tachyphylaxis — the frustrating phenomenon where a treatment gradually stops working with continued use, something very common with topical steroids.
this is a meaningful clinical advantage. However, it is worth noting that reaching clearance “at some point” during a year-long study is different from maintaining clearance throughout. Psoriasis is a chronic, relapsing condition, and VTAMA does not cure it. Patients should expect cycles of treatment and remission rather than a single course that resolves the disease permanently. For older adults or those managing cognitive conditions alongside psoriasis, the absence of tachyphylaxis is particularly relevant. A treatment that remains effective over time reduces the need for frequent medication changes, which can be confusing and destabilizing for patients with memory difficulties or their caregivers.
Why the Non-Steroidal Distinction Matters for Older Adults
One of VTAMA’s most practical advantages is what it is not: a corticosteroid. Topical steroids remain the backbone of psoriasis treatment, but they come with well-known limitations. Prolonged use can thin the skin, cause stretch marks, and lead to rebound flares when discontinued. These risks are amplified in older adults, whose skin is already thinner and more fragile. For someone in their 70s managing both psoriasis plaques and the skin vulnerability that comes with aging, steroid-related skin atrophy is a genuine concern. VTAMA has no limit on duration of use, body surface area treated, or application site — a stark contrast to topical corticosteroids, which often carry restrictions against use on the face, groin, or skin folds, and are typically recommended only for short courses.
A patient with widespread plaque psoriasis can apply VTAMA across large areas without the escalating risk profile that accompanies broad steroid application. For caregivers helping apply topical treatments to a family member with dementia and psoriasis, this simplicity matters. There is no need to track which body areas have received too many weeks of treatment or rotate between different potency steroids for different zones. That said, VTAMA is not side-effect free. The most commonly reported adverse reaction in clinical trials was folliculitis — inflammation of hair follicles that can appear as small red bumps or pustules near the application site. While generally mild, this can be uncomfortable and may be mistaken for a worsening of the psoriasis itself, potentially leading to unnecessary treatment changes if patients or caregivers are not aware of this known side effect.
VTAMA vs. Roflumilast Cream — Choosing Between the New Topicals
VTAMA is not the only new non-steroidal topical to enter the psoriasis market recently. Roflumilast cream, sold under the brand name ZORYVE, was also approved in 2022. It works as a PDE4 inhibitor, a different mechanism entirely. Both drugs represent genuine advances over the prior generation of topical treatments, but they differ in one critical respect: ZORYVE does not have a demonstrated remittive effect. It requires continuous daily application to maintain its benefits, much like traditional topical therapies. For a patient or caregiver weighing the two options, this distinction has real practical consequences.
If minimizing daily medication tasks is a priority — as it often is in households managing dementia alongside other chronic conditions — VTAMA’s intermittent dosing potential offers an advantage that ZORYVE cannot match. On the other hand, ZORYVE may have a different side-effect profile that suits certain patients better, and individual response to any psoriasis treatment is unpredictable. A drug that works beautifully for one person may do nothing for another. The decision between these two newer options, or between them and older treatments like calcipotriene or topical steroids, is best made with a dermatologist who understands the patient’s full medical picture. There is also a practical tradeoff worth acknowledging: VTAMA’s initial 12-week treatment course requires consistent daily application before any off-therapy benefit emerges. Patients who struggle with medication adherence — including those with cognitive impairment — may find it difficult to complete that initial course. A treatment requiring daily use indefinitely but with a simpler “just keep applying it” approach might paradoxically be easier to manage in some caregiving situations.
The Cost Problem That Shadows the Clinical Promise
VTAMA’s list price is approximately $140,520 per year without insurance, a figure that places it among the most expensive topical medications available. While the manufacturer offers copay assistance programs that can significantly reduce out-of-pocket costs for commercially insured patients, the sticker price creates real barriers. Medicare patients, who make up a large proportion of older adults with both psoriasis and cognitive conditions, typically cannot use manufacturer copay cards due to federal anti-kickback regulations. This leaves many in the demographic most likely to benefit from a simplified, non-steroidal, intermittent-use topical facing the steepest financial obstacles to accessing it.
Insurance coverage varies widely, and prior authorization requirements are common. Patients and caregivers should expect to navigate a process that may include documenting failure on cheaper alternatives before a plan will cover VTAMA. For families already stretched thin by the costs of dementia care — which average tens of thousands of dollars annually — adding a high-cost dermatologic medication may simply not be feasible, regardless of its clinical merits. It is also worth noting that the “four to eight weeks of use per year” framing, if it holds for a given patient, does reduce the actual quantity of cream consumed compared to a daily-use topical. Whether insurers or pharmacy benefit managers price the drug to reflect intermittent use rather than continuous use is another question entirely, and one that varies by plan.
Broader Implications — Tapinarof Beyond Psoriasis
Dermavant Sciences has been studying tapinarof for atopic dermatitis in adults and children as young as two years old, suggesting the drug’s mechanism of action through the aryl hydrocarbon receptor may have applications beyond psoriasis. If approved for atopic dermatitis, tapinarof could become relevant for an even larger patient population, including older adults who develop eczematous skin changes — a common but underrecognized issue in aging skin.
For families and caregivers already familiar with VTAMA through a psoriasis prescription, an expanded indication could simplify treatment across multiple skin conditions. However, approval for one condition does not guarantee approval for another, and the efficacy and safety profile in atopic dermatitis may differ from what has been established in psoriasis.
What This Means for Psoriasis Management Going Forward
The arrival of VTAMA marks a genuine shift in how dermatologists think about topical psoriasis treatment. The concept of a remittive topical — one that can be stopped for months at a time without immediate relapse — was not part of the clinical vocabulary before tapinarof’s trial data emerged. Even if the “four weeks a year” claim applies only to the best responders, the broader principle that intermittent topical use can maintain disease control challenges decades of assumptions about psoriasis management.
For the aging population, and particularly for those juggling psoriasis with cognitive decline or dementia caregiving, the trajectory is encouraging. As more real-world data accumulates and the drug’s place in treatment guidelines solidifies, clinicians will have a clearer picture of which patients are most likely to achieve that coveted remittive response. In the meantime, VTAMA represents a meaningful option worth discussing with a dermatologist — not as a miracle, but as a genuinely novel tool in a therapeutic area that has been short on innovation for a very long time.
Conclusion
VTAMA (tapinarof) cream offers something that no other topical psoriasis treatment currently can: a demonstrated ability to keep skin clear for months after the drug is discontinued. For some patients, this translates to dramatically less time spent applying medication each year. The drug’s non-steroidal nature, lack of body-area restrictions, and absence of tachyphylaxis make it particularly appealing for older adults and those in caregiving situations where treatment simplicity has real value.
However, the path to benefiting from VTAMA involves navigating high costs, insurance hurdles, and the reality that not every patient will achieve the kind of robust remission seen in the best trial outcomes. The “four weeks a year” possibility is real but not universal. Patients and caregivers should approach VTAMA as a promising addition to the treatment landscape — one worth exploring with a dermatologist, especially for those who have been dissatisfied with topical steroids or are looking for a regimen that demands less daily attention.
Frequently Asked Questions
Is VTAMA a steroid?
No. VTAMA (tapinarof) is a first-in-class aryl hydrocarbon receptor agonist, making it an entirely non-steroidal topical treatment. It does not carry the skin-thinning risks or duration-of-use limitations associated with topical corticosteroids.
Can VTAMA really be used for just four weeks a year?
For some patients who respond particularly well, intermittent treatment cycles could add up to as few as four to eight weeks of active use per year. However, the initial treatment course is approximately 12 weeks, and individual results vary. The four-week figure represents a best-case scenario, not a guarantee.
What is the most common side effect of VTAMA?
Folliculitis, or inflammation of hair follicles, was the most commonly reported adverse reaction in clinical trials. It typically presents as small red bumps near the application site and is generally mild.
How long does the remittive effect last after stopping VTAMA?
In the PSOARING 3 clinical trial, patients who achieved completely clear skin maintained that clearance for a mean of 130.1 days — approximately four months — after discontinuing treatment.
Does VTAMA lose effectiveness over time like topical steroids can?
No tachyphylaxis (loss of effectiveness with continued use) was observed during the 52-week PSOARING 3 long-term extension study, which is a notable advantage over many topical corticosteroids.
How much does VTAMA cost?
The list price is approximately $140,520 per year without insurance. Copay assistance programs are available for commercially insured patients, but Medicare beneficiaries often cannot access manufacturer discount programs. Actual out-of-pocket costs depend heavily on insurance coverage.
